Literature DB >> 21125678

A new era: melanoma genetics and therapeutics.

Justin M Ko1, David E Fisher.   

Abstract

We have recently witnessed an explosion in our understanding of melanoma. Knowledge of the molecular basis of melanoma and the successes of targeted therapies have pushed melanoma care to the precipice of a new era. Identification of significant pathways and oncogenes has translated to the development of targeted therapies, some of which have produced major clinical responses. In this review, we provide an overview of selected key pathways and melanoma oncogenes as well as the targeted agents and therapeutic approaches whose successes suggest the promise of a new era in melanoma and cancer therapy. Despite these advances, the conversion of transient remissions to stable cures remains a vital challenge. Continued progress towards a better understanding about the complexity and redundancy responsible for melanoma progression may provide direction for anti-cancer drug development.
Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21125678     DOI: 10.1002/path.2804

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  44 in total

1.  Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model.

Authors:  Elizabeth A Vasievich; Srinivas Ramishetti; Yuan Zhang; Leaf Huang
Journal:  Mol Pharm       Date:  2011-12-28       Impact factor: 4.939

2.  The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type.

Authors:  Elke Stadelmeyer; Ellen Heitzer; Margit Resel; Lorenzo Cerroni; Peter Wolf; Nadia Dandachi
Journal:  J Invest Dermatol       Date:  2013-08-09       Impact factor: 8.551

3.  TBC1D16 is a Rab4A GTPase activating protein that regulates receptor recycling and EGF receptor signaling.

Authors:  Basem S Goueli; Marianne Broome Powell; Elizabeth C Finger; Suzanne R Pfeffer
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

Review 4.  [Treatment of advanced metastatic melanoma].

Authors:  S Ugurel; J C Becker
Journal:  Hautarzt       Date:  2011-06       Impact factor: 0.751

5.  Down-regulation of tissue microRNA-126 was associated with poor prognosis in patients with cutaneous melanoma.

Authors:  Nengxing Lin; Yu Zhou; Xin Lian; Yating Tu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

6.  Management of conjunctival malignant melanoma: a review and update.

Authors:  James R Wong; Afshan A Nanji; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2014-06

7.  Opportunities and challenges in the development of experimental drug combinations for cancer.

Authors:  Rachel W Humphrey; Laura M Brockway-Lunardi; David T Bonk; Kathleen M Dohoney; James H Doroshow; Sandra J Meech; Mark J Ratain; Suzanne L Topalian; Drew M Pardoll
Journal:  J Natl Cancer Inst       Date:  2011-07-15       Impact factor: 13.506

8.  Inhibition of melanoma growth by small molecules that promote the mitochondrial localization of ATF2.

Authors:  Tal Varsano; Eric Lau; Yongmei Feng; Marine Garrido; Loribelle Milan; Susanne Heynen-Genel; Christian A Hassig; Ze'ev A Ronai
Journal:  Clin Cancer Res       Date:  2013-04-15       Impact factor: 12.531

9.  Primary retroperitoneal malignant melanoma: A case report.

Authors:  Guo-Bing Liu; Guang-Yao Wu; Prasanna Ghimire; Zai-Peng Zhang
Journal:  Oncol Lett       Date:  2011-08-29       Impact factor: 2.967

Review 10.  Optimal management of metastatic melanoma: current strategies and future directions.

Authors:  Marta Batus; Salman Waheed; Carl Ruby; Lindsay Petersen; Steven D Bines; Howard L Kaufman
Journal:  Am J Clin Dermatol       Date:  2013-06       Impact factor: 7.403

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.